Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors

This publication has 38 references indexed in Scilit:

• Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias
  Seminars in Oncology, 2003
• Nocodazole-induced p53-dependent c-Jun N-terminal Kinase Activation Reduces Apoptosis in Human Colon Carcinoma HCT116 Cells
  Journal of Biological Chemistry, 2002
• Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer
  Expert Opinion on Investigational Drugs, 2002
• Interleukin-6 Is an Autocrine Growth Factor in Human Prostate Cancer
  The American Journal of Pathology, 2001
• Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer
  Expert Opinion on Investigational Drugs, 2001
• Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
  New England Journal of Medicine, 2001
• Apaf-1/Cytochrome c-independent and Smac-dependent Induction of Apoptosis in Multiple Myeloma (MM) Cells
  Journal of Biological Chemistry, 2001
• Circulating concentrations of insulin-like growth factor I and risk of breast cancer
  The Lancet, 1998
• The Insulin-Like Growth Factor-I Receptor Signaling Pathways Are Important for Tumorigenesis and Inhibition of Apoptosis
  Critical Reviews™ in Oncogenesis, 1997
• Nonparametric Estimation from Incomplete Observations
  Journal of the American Statistical Association, 1958